GC Biopharma has successfully developed and validated a proprietary assay designed to precisely measure impurities linked to thromboembolic risks. This breakthrough represents a significant advancement in the safety monitoring of intravenous immunoglobulin (IVIG) therapies.
Key highlights of this technology include:
-
Overcoming traditional analytical limitations: In IVIG therapies, high concentrations of IgG often cause signal interference, leading to false positives or difficulties in detecting impurities. GC Biopharma’s enhanced ELISA assay utilizes a selective IgG blocker to eliminate non-specific protein reactions.
-
Precise measurement of coagulation factors: The new method allows for the isolated and accurate measurement of Factor XI (FXI), a critical impurity directly associated with thromboembolic events. Strict monitoring of FXI levels is mandated by global regulatory bodies, including the U.S. FDA, to ensure patient safety.
-
International Standards: The analytical platform has been fully validated in accordance with the International Council for Harmonisation Q2(R2) guidelines.
-
Manufacturing Application: GC Biopharma’s R&D leadership stated that establishing this advanced analytical framework significantly elevates quality control capabilities for plasma-derived protein therapies, ensuring the supply of high-quality products to the global market.
The detailed study regarding this proprietary platform was officially published in the April 2026 issue of the Journal of Microbiology and Biotechnology.